NCT03480672已完成2 期
Postoperative Adjuvant Radiochemotherapy (aRCH) With Cisplatin (C) Versus aRCH With C and Pembrolizumab (P) in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC); Multicenter Randomized Phase II Study Within the German Interdisciplinary Study Group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk
University of Leipzig16 个研究点 分布在 1 个国家目标入组 211 人开始时间: 2018年8月6日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 211
- 试验地点
- 16
- 主要终点
- Event Free Survival (EFS)
研究概览
简要总结
This trial evaluates the addition of pembrolizumab to standard postoperative adjuvant radiochemotherapy in the treatment of patients with locally advanced intermediate and high risk head and neck squamous cell carcinoma (HNSCC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Macroscopically complete resection of newly diagnosed (not recurrent, not secondary primary) advanced squamous-cell carcinoma arising in the oral cavity, oropharynx, larynx, or hypopharynx
- •Advanced stage III, IVA/B HNSCC according to the TNM classification version 7th edition (Note! The 8th edition will not be used, please adhere to the national cancer institute guidelines)
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; performance status allows adjuvant chemo radiation with cisplatin.
- •Had either intermediate or high-risk characteristics, i.e. any or all of the following:
- •histologic evidence of invasion of two or more regional lymph nodes
- •extracapsular extension of nodal disease,
- •microscopically involved mucosal margins of resection (R1) or margins of resection < 5mm (R0)
- •Had pathological histologic assessment of p16 (only oropharyngeal carcinoma)
- •Be > 18 years of age
- •Written informed consent
- •Demonstrate adequate organ function
- •Female subject of childbearing potential should have a negative pregnancy test within 3 days prior to receiving the first dose of study medication.
- •Female subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication.
- •Reproductive male subjects must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy
排除标准
- •Concurrent participation in any other interventional clinical trial or participation in any other interventional trial within one month before enrolment into this trial.
- •Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before enrolment into this trial.
- •Known history of active TB (Bacillus Tuberculosis)
- •Hypersensitivity to Pembrolizumab or comparable medicinal products or any of its excipients.
- •Prior anti-cancer monoclonal antibody (mAb) therapy within one month before enrolment into this trial or who has not recovered (i.e., ≤ Grade 1 (NCI CTCAE Grade) at baseline) from adverse events due to agents administered more than one month earlier.
- •Prior chemotherapy, targeted small molecule therapy, or radiation therapy within one month before enrolment into this trial or who has not recovered (i.e., ≤ grade 1 (NCI CTCAE Grade) at baseline) from adverse events due to a previously administered agent.
- •Note: Subjects with ≤ Grade 2 (NCI CTCAE Grade) neuropathy are an exception to this criterion and may qualify for the study.
- •Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
- •Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
- •Active autoimmune disease that has required systemic treatment in the past 2 years prior to enrolment (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •Evidence of interstitial lung disease or history of (non-infectious) pneumonitis that required steroids within the last 6 months before enrolment into this trial, or current pneumonitis.
- •Active infection requiring systemic therapy.
- •Suspected lack of compliance
- •Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the baseline visit through 120 days after the last dose of trial treatment.
- •HIV, HBV or HCV infection
- •Application of a live vaccine within one month of enrolment.
- •Hypersensitivity to cisplatin or any of its excipients
- •Any potential relationship to the investigator/his deputy or to medical staff of the study team, to the coordinating investigator or is an employee of the study sit
研究组 & 干预措施
Pembrolizumab + aRCH
Experimental
Application of pembrolizumab, i.v., in 3-week cycle (q3w) 200 mg, in combination with standard treatment (adjuvant radio-chemotherapy aRCH)
干预措施: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA] (Drug)
Pembrolizumab + aRCH
Experimental
Application of pembrolizumab, i.v., in 3-week cycle (q3w) 200 mg, in combination with standard treatment (adjuvant radio-chemotherapy aRCH)
干预措施: adjuvant radiochemotherapy (Other)
aRCH
Active Comparator
adjuvant radio-chemotherapy (aRCH)
干预措施: adjuvant radiochemotherapy (Other)
结局指标
主要结局
Event Free Survival (EFS)
时间窗: 24 months
time from randomization to the first event (i.e. locoregional or distant recurrence, initiation of a new anti-cancer treatment death from any cause)
次要结局
- Overall survival (OS)(24 months)
研究者
Andreas Dietz
Prof. Dr. med.
University of Leipzig
研究点 (16)
Loading locations...
相似试验
终止
2 期
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung CancerLimited Stage Lung Small Cell CarcinomaStage I Lung CancerStage II Lung CancerStage III Lung CancerNCT06140407Vanderbilt-Ingram Cancer Center1
Unknown
2 期
Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )ESCCAdjuvant TreatmentLymph Node PositivePembrolizumabNCT04863079Tianjin Medical University Cancer Institute and Hospital82
已完成
1 期
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant MesotheliomaPleural Malignant MesotheliomaNCT02959463M.D. Anderson Cancer Center25
进行中（未招募）
2 期
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction CancerClinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Esophageal AdenocarcinomaEsophageal Squamous Cell CarcinomaPathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8NCT04929392City of Hope Medical Center3
招募中
2 期
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCCHead and Neck Squamous Cell CarcinomaNCT06170710Cancer Institute and Hospital, Chinese Academy of Medical Sciences173